Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings

Schizophrenia Research

Volumn 166, Issue 1-3, 2014, Pages 201-206

  Enez Darcin, Asli ^a   Yalcin Cavus, Sercin ^b   Dilbaz, Nesrin ^c   Kaya, Hasan ^d   Dogan, Eylem ^e  

^a Kanuni SS Training and Research Hospital   (Turkey)

^b Madalyon Psychiatry Center   (Turkey)

^c USKUDAR UNIVERSITY   (Turkey)

^d Gaziantep 25 Aralik Hospital   (Turkey)

^e Viransehir State Hospital   (Turkey)

Author keywords

Drug free; Drug naive; Metabolic syndrome; Schizophrenia; Siblings

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIBLING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; COMORBIDITY; FAMILY; METABOLIC DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; TURKEY;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; COMORBIDITY; FAMILY; FEMALE; HUMANS; MALE; METABOLIC DISEASES; PREVALENCE; SCHIZOPHRENIA; TURKEY;

EID: 84955401330     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.05.004     Document Type: Article

References (37)

1. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Arango C., Bobes J., Aranda P., Carmena R., Garcia-Garcia M., Rejas J., CLAMORS Study Collaborative Group A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr. Res. 2008, 104:1-12.
3. Baptista T., Serrano A., Uzcátegui E., ElFakih Y., Rangel N., Carrizo E., Fernández V., Connell L., de Baptista E.A., Quiroz S., Uzcátegui M., Rondón J., Matos Y., Uzcátegui L., Gómez R., Valery L., Novoa-Montero D. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: Comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela. Schizophr. Res. 2007, 126:93-102.
4. Black D.W., Fisher R. Mortality in DSM-III-R schizophrenia. Schizophr. Res. 1992, 7:109-116.
5. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br. J. Psychiatry 1997, 171:502-504.
6. Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry 2000, 177:212-217.
7. Cerit C., Özten E., Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk. J. Psychiatry 2008, 19:124-132.
8. Cohn T.A., Remmington G., Zipursky R.B., Azad A., Connolly P., Wolever M.S. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can. J. Psychiatry 2006, 51:382-386.
9. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr. Res. 2007, 89:91-100.
10. Curkendall S.M., Mo J., Glasser D.B., Rose Stang M., Jones J.K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J. Clin. Psychiatry 2004, 65(5):715-720.
11. De Hert M.A., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 2006, 83(1):87-93.
12. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin. Pract. Epidemiol. Ment. Health 2006, 2:14.
13. De Hert M., Schreurs V., Vancampfort D., Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009, 8(1):15-22.
14. De Hert M., Mauri M., Shaw K., Wetterling T., Doble A., Giudicelli A., Falissard B. The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. Int. J. Methods Psychiatr. Res. 2010, 19:195-210.
15. Fernandez-Egea E., Bernardo M., Parellada E., Justicia A., Garcia-Rizo C., Esmatjes E., Conget I., Kirkpatrick B. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr. Res. 2008, 103(1-3):110-113.
16. Fernandez-Egea E., Miller B., Bernardo M., Donner T., Kirkpatrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr. Res. 2008, 98(1-3):302-306.
17. Grover S., Aggarwal M., Dutt A., Chakrabarti S., Avasthi A., Kulhara P., Somaiya M., Malhotra N., Chauhan N. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry Res. 2012, 200:1035-1037.
18. Grover S., Nebhinani N., Padmavati R., Chadda R.K., Tirupati S., Pallava A. Metabolic syndrome in antipsychotic naïve patients with schizophrenia: pooled analysis of data from three Indian studies. Early Interv. Psychiatry 2014, ([Epub ahead of print]). 10.1111/eip.12117.
19. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J., National Lung and Heart Blood Institute, American College of Cardiology Foundation, American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
20. Heiskanen T., Niskanen L., Lyytikainen R., Saarinen P.I., Hintikka J. Metabolic syndrome in patients with schizophrenia. J. Clin. Psychiatry 2003, 64(5):575-579.
21. Henderson D.C., Fan X., Sharma B., Copeland P.M., Borba C.P., Freudenreich O., Cather C., Evins A.E., Goff D.C. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. J. Psychiatr. Pract. 2009, 15(4):251-261.
22. IDF Consensus IDF The IDF Consensus Worldwide Definition of the Metabolic Syndrome http://www.idf.org.
23. Kato M.M., Currier M.B., Gomez C.M., Hall L., Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim. Care Comp. J. Clin. Psychiatry 2004, 6:74-77.
24. Kozan O., Oguz A., Abaci A., Erol C., Ongen Z., Çelik S. Prevalence of the metabolic syndrome among Turkish adults. Eur. J. Clin. Nutr. 2007, 61(4):548-553.
25. Malhotra N., Grover S., Chakrabarti S., Kulhara P. Metabolic syndrome in schizophrenia. Indian J. Psychol. Med. 2013, 35(3):227-240.
26. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
27. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr. Bull. 2013, 39:306-318.
28. Mukherjee S., Schnur D.B., Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989, 1:495.
29. Osby U., Correia N., Brandt L., Ekbom A., Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 2000, 45:21-28.
30. Pallava A., Chadda R.K., Sood M., Lakshmy R. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. Nord. J. Psychiatry 2012, 66:215-221.
31. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
32. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying Kin Ng, Stip E., Baptista T., Malla A., Joober R. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls. Schizophr. Res. 2008, 102(1-3):329-336.
33. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 2007, 24:481-485.
34. Valsamakis G., Chetty R., Anwar A., Banerjee A.K., Barnett A., Kumar S. Association of simple anthropometric measures of obesity with visceral fat and the metabolic syndrome in male Caucasian and Indo-Asian subjects. Diabet. Med. 2004, 21(12):1339-1345.
35. Vancampfort D., Wampers M., Mitchell A.J., Correll C.U., De Herdt A., Probst M., De Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013, 12(3):240-250.
36. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., Thirthall J., Gangadhar B.N., Shetty K.T. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am. J. Psychiatry 2007, 164:1557-1560.
37. Verma S.K., Subramaniam M., Liew A., Poon L.Y. Metabolic risk factors in drug-naive patients with first-episode psychosis. J. Clin. Psychiatry 2009, 70(7):997-1000.